Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Sees Significant Decline in Short Interest

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) was the recipient of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totaling 15,577 shares, a decrease of 51.9% from the May 31st total of 32,362 shares. Currently, 2.8% of the company’s shares are sold short. Based on an average daily volume of 23,991 shares, the days-to-cover ratio is presently 0.6 days.

Sigyn Therapeutics Stock Performance

OTCMKTS:SIGY remained flat at $0.04 during mid-day trading on Tuesday. The company’s stock had a trading volume of 5,247 shares, compared to its average volume of 8,794. The company has a market cap of $93,218.00, a PE ratio of -0.01 and a beta of -0.06. The stock’s fifty day moving average price is $0.04 and its two-hundred day moving average price is $0.45. Sigyn Therapeutics has a 12-month low of $0.01 and a 12-month high of $5.00.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.